Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats-Reference-Cited by-同舟云学术

Dual amylin and calcitonin receptor agonist treatment reduces biomarkers associated with kidney fibrosis in diabetic rats

Published:2023-11-01 Issue:5 Volume:325 Page:E529-E539
ISSN:0193-1849
Container-title:American Journal of Physiology-Endocrinology and Metabolism
language:en
Short-container-title:American Journal of Physiology-Endocrinology and Metabolism

Author:

Melander Simone Anna¹²^ORCID,Møller Alexandra Louise¹²,Mohamed Khaled Elhady¹,Rasmussen Daniel Guldager Kring¹,Genovese Federica¹,Karsdal Morten Asser¹³,Henriksen Kim¹³,Larsen Anna Thorsø¹^ORCID

Affiliation:

1. Nordic Bioscience, Herlev, Denmark

2. Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark

3. KeyBioscience AG, Stans, Switzerland

Abstract

These studies describe the beneficial effects of using a dual amylin and calcitonin receptor agonist (DACRA) for diabetes-related kidney complications. DACRA treatment reduced levels of serological biomarkers associated with kidney fibrosis. These reductions were further reflected by reduced collagen expression in diabetic kidneys. In general, these results validate the use of serological biomarkers while demonstrating the potential effect of DACRAs in treating diabetes-related long-term complications.

Funder

The Danish Research Foundation

Innovationsfonden

Publisher

American Physiological Society

Subject

Physiology (medical),Physiology,Endocrinology, Diabetes and Metabolism

Link

https://journals.physiology.org/doi/pdf/10.1152/ajpendo.00245.2023

Reference59 articles.

1. Obesity: global epidemiology and pathogenesis

2. Obesity in adults: a clinical practice guideline

3. Vascular complications in patients with type 2 diabetes: prevalence and associated factors in 38 countries (the DISCOVER study program)

4. Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy